- Strategic initiatives and pipeline advancements support clinical development of CYB003 and CYB004 exploring potential therapeutic benefits using psychedelic-based molecules - TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin
WINNIPEG, Manitoba--(BUSINESS WIRE)--First paragraph, second sentence of release should read: The dividend is payable on January 13, 2023 to common shareholders of record at the close of business on December 30, 2022. (instead of The dividend is payable o
WINNIPEG, Manitoba--(BUSINESS WIRE)--Ag Growth International Inc. (“AGI”) (TSX: AFN) today announced a new distribution partnership with Ada Manufacturing Corporation (ADAMCO), the largest dealer of farm machinery across the Philippines with over 30 b
Zanidatamab as monotherapy produced a confirmed objective response rate (cORR) of 41.3% and median duration of response of 12.9 months in patients with previously treated HER2-amplified and expressing biliary tract cancers (BTC) Pending receipt of reg
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--$IMV #CancerVaccine--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immu
HOUSTON--(BUSINESS WIRE)--DXP Enterprises, Inc. (NASDAQ: DXPE) today announced that its Board of Directors authorized a new stock repurchase program (the “program”) under which up to $85.0 million or 2.8 million shares of its outstanding common stock
BioStrand Completes Integration of 20 Million Proprietary Structural HYFTs™ used as a navigational layer to parse over the protein predictive platforms AlphaFold-2 and Evolutionary Scale Modeling (ESM)-2 Fold HYFTs are now linked together by more th
OTTAWA, Ontario--(BUSINESS WIRE)--#HR--BioTalent Canada has been named one of the country’s Best Workplaces™ for Mental Wellness and Best Workplaces™ in Healthcare for 2022. These recognitions come from Great Place to Work™ Canada and cap a progr
Complete responses were observed in patients who received at least three previous lines of treatment (including CAR-T's) Recent clinical data add to the growing enthusiasm for the therapeutic potential of cancer vaccines in combination with checkpoint i
VANCOUVER, British Columbia--(BUSINESS WIRE)--$ABCL--AbCellera (Nasdaq: ABCL) announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. (NYSE: ABBV). The partnership will leverage AbCellera’s antibody d
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.